Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Most local anesthetics act by abolishing voltage gated sodium channel currents indiscriminately in all populations of neurons. Selective analgesia through TRPV1-mediated entry of a cationic lidocaine derivative, QX314, was recently reported. CAY10568 is a physically smaller, less hydrophobic version of QX314 designed to be even more permeable to TRPV1 ion channel when activated by agonists such as capsaicin and N-oleoyl dopamine. CAY10568 when given in combination with suitable TRPV1 agonists should produce selective blockade of the pain response while leaving motor, touch, and proprioception intact.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | 35 days | $ 93.00 | |
25 mg | 35 days | $ 215.00 | |
50 mg | 35 days | $ 394.00 | |
100 mg | 35 days | $ 693.00 |
Description | Most local anesthetics act by abolishing voltage gated sodium channel currents indiscriminately in all populations of neurons. Selective analgesia through TRPV1-mediated entry of a cationic lidocaine derivative, QX314, was recently reported. CAY10568 is a physically smaller, less hydrophobic version of QX314 designed to be even more permeable to TRPV1 ion channel when activated by agonists such as capsaicin and N-oleoyl dopamine. CAY10568 when given in combination with suitable TRPV1 agonists should produce selective blockade of the pain response while leaving motor, touch, and proprioception intact. |
Molecular Weight | 320.174 |
Formula | C11H17IN2O |
CAS No. | 22913-17-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PBS (pH 7.2): 0.5 mg/mL
DMF: 5 mg/mL
DMSO: 3 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CAY10568 22913-17-3 CAY-10568 CAY 10568 inhibitor inhibit